NOVARTIND vs SYMBIOTEC: Stock Comparison
SYMBIOTEC PHARMALAB is the larger company by market capitalisation. NOVARTIS INDIA shows faster revenue growth and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
NOVARTIND leads 2; SYMBIOTEC leads 1 of 4
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | NOVARTIND | SYMBIOTEC |
|---|---|---|
| Sector | Healthcare | — |
| Industry | Pharmaceuticals | — |
Price
| Metric | NOVARTIND | SYMBIOTEC |
|---|---|---|
| Live Price | ₹2,139.8 | ₹1,038.6 |
| Day Change | 7.23% | -0.4% |
| Volume | 1.14 L | 2.75 L |
| 52-Week High | ₹2,588.8 | ₹1,193.7 |
| 52-Week Low | ₹950 | ₹934.2 |
| Distance from 52W High | -17.34% | -12.99% |
Valuation
| Metric | NOVARTIND | SYMBIOTEC |
|---|---|---|
| Market Cap | ₹5,286 Cr | ₹6,624 Cr |
| P/E Ratio | 50.32x | — |
| P/B Ratio | 6.02x | — |
| EPS | ₹13.05 | — |
| Book Value | ₹331.23 | — |
| Dividend Yield | 0% | 0% |
Growth
| Metric | NOVARTIND | SYMBIOTEC |
|---|---|---|
| Revenue Growth (TTM YoY) | 8% | 0% |
| EPS Growth (TTM YoY) | -13.8% | 0% |
| Qtr Sales Growth | -70.7% | — |
| Qtr Profit Growth | -65.43% | — |
Profitability & Leverage
| Metric | NOVARTIND | SYMBIOTEC |
|---|---|---|
| ROE | 11.39% | — |
| ROCE | 14.33% | — |
| Net Margin | 26.3% | 0% |
| Operating Margin | 36.95% | — |
| Debt to Equity | 0x | — |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | NOVARTIND | SYMBIOTEC |
|---|---|---|
| Promoter Holding | 0% | 33.28% |
| FII Holding | 0.16%▼ 0.01 pp | 21.08% |
| DII Holding | 1.36%▲ 0.83 pp | 27.52% |
| Public Holding | 27.8%▼ 0.81 pp | 18.12% |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: NOVARTIS INDIA and SYMBIOTEC PHARMALAB.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.